Federal Register of Legislation - Australian Government

Primary content

Determinations/Health as made
This instrument amends the Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018 to enable testing provided under item 73343 for patients with relapsed or refractory chronic lymphoid leukaemia or small lymphocytic lymphoma, to determine eligibility for venetoclax, in addition to ibrutinib and idelalisib, under the Pharmaceutical Benefits Scheme.
Administered by: Health
Registered 22 Feb 2019
Tabling HistoryDate
Tabled HR02-Apr-2019
Tabled Senate02-Apr-2019
Date of repeal 12 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.


I, CELIA STREET, delegate of the Minister for Health, make the following determination.

Dated            20 February 2019




Celia Street

Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medical Benefits Division

Department of Health












1.               Name                                                                                                     3

2.               Commencement                                                                                       3

3.               Authority                                                                                                 3

4.               Schedules                                                                                                3

Schedule      1 – Amendments                                                                              4











1.                       Name

This instrument is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No.2) 2019.

2.                       Commencement

This instrument commences on 1 March 2019.

3.                       Authority

This instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

4.                       Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.



Schedule 1 – Amendments


Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1                   Schedule 1 (item 73343, column 2)

Omit “idelalisib or ibrutinib”, substitute “idelalisib, ibrutinib or venetoclax”.